NCT06318676View on ClinicalTrials.gov

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2024

Conditions

Renal Impairment

Interventions

DRUG

Mezigdomide

Specified dose on specified days

Trial Locations (3)

32806

Omega Research Group - Orlando, Orlando

32809

Orlando Clinical Research Center OCRC, Orlando

33014

PANAX, Miami Lakes

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celgene

INDUSTRY